Found 162 articles for: "infliximab"
Trends in Older Adult Psoriasis Outpatient Health Care Practices in the United States
August 2012 | Volume 11 | Issue 8 | Original Article | 957 | Copyright © August 2012
Background: Psoriasis is among the top dermatologic diagnoses for older adult patients, and the number of older adult psoriasis patients is expected to rise.
Purpose: To characteri...
Read MoreOpen Label Study to Evaluate the Efficacy of Re-Treatment With Etanercept in Patients With Psoriasis
August 2012 | Volume 11 | Issue 8 | Original Article | 950 | Copyright © August 2012
Background: Etanercept has been used to treat chronic plaque psoriasis. Previously reported data demonstrated that some patients experienced secondary failure and frequently rotational-switch t...
Read MoreUstekinumab Improves Health-Related Quality of Life in Korean and Taiwanese Patients With Moderate to Severe Psoriasis: Results from the PEARL Trial
August 2012 | Volume 11 | Issue 8 | Original Article | 943 | Copyright © August 2012
Background: The PEARL study showed that the proportion of psoriasis patients achieving the primary endpoint (at least 75% improvement from baseline to week 12 in the Psoriasis Area and Severity...
Read MoreTreatment of Nail Psoriasis With TNF-α or IL12/23 Inhibitors
August 2012 | Volume 11 | Issue 8 | Original Article | 939 | Copyright © August 2012
Nail psoriasis appears to be an important source of psoriatic morbidity through physical impairment, pain, and cosmetic disturbances. Conventional treatment is often unsatisfactory. A systematic revie...
Read MoreJAK Inhibitors in Psoriasis: A Promising New Treatment Modality
August 2012 | Volume 11 | Issue 8 | Original Article | 913 | Copyright © August 2012
Background: Inflammatory cytokines play a crucial role in the pathophysiology of psoriasis. New therapies are targeting Janus kinases (JAKs), enzymes involved with transduction of cytokine rece...
Read MoreInfliximab (Remicade) and Increased Incidence of Development of Basal Cell Carcinoma
May 2012 | Volume 11 | Issue 5 | Case Reports | 655 | Copyright © May 2012
Immunosuppression is a known risk factor for the development of non-melanoma skin cancers (NMSC). Certain medications that induce immunosuppression, such as tumor necrosis factor-α (TNF-α) i...
Read MoreSarcoidosis as an Adverse Effect of Tumor Necrosis Factor Inhibitors
May 2012 | Volume 11 | Issue 5 | Original Article | 609 | Copyright © May 2012
Background: Tumor necrosis factor inhibitors are valuable tools for dermatologists. As their use increases, rare adverse events are more likely to be encountered.
Objective: We des...
Read MoreTreatment of Generalized Vitiligo With Anti-TNF-α Agents
April 2012 | Volume 11 | Issue 4 | Case Reports | 534 | Copyright © April 2012
Background: Although the exact pathogenesis of vitiligo is not fully understood, it appears to be an autoimmune disease. It is hypothesized that tumor necrosis factor alpha (TNF-α) plays ...
Read MoreA Phase 2, Open-Label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Allergic Contact or Atopic Dermatitis
March 2012 | Volume 11 | Issue 3 | Original Article | 341 | Copyright © March 2012
Objective: Evaluate the efficacy and safety of apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, in subjects with recalcitrant moderate to severe atopic dermatitis (AD) or allergic cont...
Read MoreTreatment of Ulcerated Necrobiosis Lipoidica With Intravenous Immunoglobulin and Methylprednisolone
February 2012 | Volume 11 | Issue 2 | Case Reports | 256 | Copyright © February 2012
The authors report a female patient with recalcitrant ulcerated necrobiosis lipoidica (NL) that was resistant to numerou...
Read MoreUstekinumab: A Review in the Treatment of Plaque Psoriasis and Psoriatic Arthritis
February 2012 | Volume 11 | Issue 2 | Original Article | 160 | Copyright © February 2012
Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably affects the skin, nails, and joints. In September 2009, ustekinumab (Stelara®), a monoclonal antibody that ta...
Read MoreTransient Improvement in Chronic Psoriasis After Treatment of TNF-α Blocker Induced Disseminated M. Tuberculosis Infection
January 2012 | Volume 11 | Issue 1 | Case Reports | 119 | Copyright © January 2012
Improvement in psoriasis after treatment of reactivated latent tuberculosis following initiation of TNF-α inhibitor therapy has yet to be described in the literature. The authors present a case o...
Read MoreNews, Views, & Reviews
Manifestations and Treatment of Cutaneous Lupus Erythematosus (Part II of II)December 2011 | Volume 10 | Issue 12 | Features | 1474 | Copyright © December 2011
Treatment of Recalcitrant Generalized Granuloma Annulare With Adalimumab
December 2011 | Volume 10 | Issue 12 | Case Reports | 1466 | Copyright © December 2011
Granuloma annulare is a benign, usually self-limited, dermatosis of unknown cause. Generalized lesions occur in approxi...
Read MoreTreatment of Peristomal Pyoderma Gangrenosum With Topical Crushed Dapsone
September 2011 | Volume 10 | Issue 9 | Case Reports | 1059 | Copyright © September 2011
A 27-year-old male with a history of Crohn's disease was treated for chronic pyoderma gangrenosum at his stoma site. Treatment with topical application of crushed dapsone resulted in improvement of hi...
Read MoreMycobacterium Fortuitum Infection Following Adalimumab Treatment for Psoriasis and Subsequent Complication-Free Treatment With Alternate TNF-α Blockers
August 2011 | Volume 10 | Issue 8 | Case Reports | 914 | Copyright © August 2011
Tumor necrosis factor-α (TNF-α) inhibitors, such as adalimumab, are often used to treat psoriasis and psoriatic arthritis. While it is well known that these agents increase the risk of react...
Read MoreClobetasol Propionate 0.05% Spray for the Management of Moderate-to-Severe Plaque Psoriasis of the Scalp: Results From a Randomized Controlled Trial
August 2011 | Volume 10 | Issue 8 | Original Article | 885 | Copyright © August 2011
Background: Clobetasol propionate 0.05% spray is available for treating moderate-to-severe plaque psoriasis; however, there is limited inform...
Read MoreA Retrospective Study to Investigate Racial and Ethnic Variations in the Treatment of Psoriasis With Etanercept
August 2011 | Volume 10 | Issue 8 | Original Article | 866 | Copyright © August 2011
Objectives: Psoriasis is a chronic inflammatory condition that occurs worldwide; however, few studies have examined this condition ...
Read MoreIncreased Prevalence of Psychiatric Disorders and Health Care-Associated Costs Among Patients With Moderate-to-Severe Psoriasis
August 2011 | Volume 10 | Issue 8 | Original Article | 843 | Copyright © August 2011
Objective: To characterize the prevalence of psychiatric disorders in patients with moderate-to-severe psoriasis and compare health care costs between patients with and without psychiatric como...
Read MoreAcitretin in Dermatology: A Review
July 2011 | Volume 10 | Issue 7 | Original Article | 772 | Copyright © July 2011
Introduction: Acitretin is a systemic retinoid drug used in the treatment of severe psoriasis. It has also been used for a spectrum of other...
Read More